GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently undervalued according to InvestingPro Fair Value metrics, has reached a ...
Zacks.com on MSN13d
EMA Accepts GSK's Filing for Depemokimab in Two Respiratory DiseasesGSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...
Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...
GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...
Key drugs Blenrep and Depemokimab show significant potential, with impressive Phase 3 results, expected to boost GSK's revenues by an extra £7 billion. Despite some IRA and clinical trial risks ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...
GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use ...
https://www.tipranks.com/news/the-fly/cigna-price-target-lowered-to-350-from-400-at-cantor-fitzgerald GSK (GSK) announced that the European Medicines Agency, EMA, has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback